Drugs / CX1003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04093466 | Apr 2020 → Oct 2025 overdue | neoplasm | Beijing Konruns Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CX1003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04093466 ↗ |
| Known as | Kanitinib | “A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors” NCT04093466 ↗ |
| Action | Inhibit | “primarily inhibit vascular endothelial growth factor receptor 2 (VEGFR2) and hepatocyte growth factor receptor (HGFR/MET)” NCT04093466 ↗ |
| Modality | Small molecule | “CX1003 is a novel multi-target tyrosine kinase inhibitor” NCT04093466 ↗ |
| Route | Oral | “Oral dose” NCT04093466 ↗ |